



# GR Aktien Schweiz Small & Mid Caps -R-

31 December 2024

## Investment Policy

The fund invests into equity securities of companies which are part of the SPI Extra Index (SPIEX). Stock selection is based on a bottom-up research process which also includes sustainability criteria (ESG). Core investments consist of high-quality companies which generate high levels of free cash flow and are reasonably priced. The fund consists of 45-55 companies.

## Market environment, performance analysis and portfolio activity


In December, mainly Technology stocks were able to make further significant gains. Notably, US index heavyweights like Alphabet, Amazon, Apple and Tesla recorded substantial price increases. On the other hand, the Russell 2000, which includes smaller US companies, lost a large part of its strong November performance. This could also be related to the rising interest rates over the course of the month. The development of interest rates could come more into the focus of investors in the coming months, depending on the implementation of the Trump agenda.

The SPI Extra index also continued to lose value in December and ended the last quarter significantly in the red. The relative monthly performance was positively impacted by overweighted Temenos, SGS and Aryzta as well as by underweighted Bachem and Sunrise. Negatively affected was the relative performance by overweighted Siegfried, Comet and SoftwareOne as well as by underweighted Avolta and Flughafen Zürich. In December, we added to our holdings in Galderma and Ypsomed while reducing our positions in Julius Baer. Orior has been sold completely.

## Fund Information

<b>Fund Managers</b>	Adrian Peter Martin Würmli
<b>Custodian Bank</b>	Privatbank Von Graffenried AG
<b>Fund Management</b>	1741 Fund Solutions AG
<b>Fund Domicile / Distribution License</b>	Switzerland
<b>Inception Date</b>	04 June 2009
<b>ISIN</b>	CH0182687126
<b>Valor</b>	18268712
<b>Bloomberg Ticker</b>	GRAKSMR SW
<b>Minimum investment</b>	CHF 0
<b>Morningstar Rating (5 Years)</b>	★★★
<b>ESG-Rating (MSCI)</b>	AA
<b>Benchmark</b>	SPIEX TR
<b>Management Fee p.a.</b>	1.40%
<b>Custodial Fee p.a.</b>	0.10%
<b>TER p.a.</b>	1.51%
<b>Redemption Fee (FBO the fund)</b>	0.50%
<b>Fund Currency</b>	CHF
<b>Net Asset Value</b>	222.89
<b>Fund Assets (in Mio.)</b>	285.2
<b>Distribution</b>	1.35
<b>Last Distribution</b>	24 April 2024

## Performance indexed (Basis 100)



## Performance

in %	YTD	1 Mo	3 Mo	6 Mo	1 Y	2 Y	3 Y	5 Y	10 Y
<b>Fund</b>	2.29	-1.28	-6.33	-2.47	2.29	10.98	-15.70	11.83	81.18
<b>SPIEX TR</b>	3.83	-0.83	-4.97	-0.66	3.83	10.61	-15.95	10.99	87.21

<b>Subscription/Redemption</b>	daily until 3:00 pm
<b>Contact</b>	+41 31 320 51 61

## Key Figures

	1 year	3 years
<b>Alpha</b>	-1.68%	0.10%
<b>Beta</b>	1.05	1.00
<b>Correlation</b>	0.99	0.99
<b>Volatility p.a.</b>	8.46%	14.37%
<b>Sharpe Ratio</b>	0.12	negative
<b>Tracking Error p.a.</b>	1.45%	1.70%
<b>Information Ratio</b>	negative	0.06

## Breakdown by Sectors

Industrial & Services	31.3%
Health Care	17.2%
Financial Services	13.9%
Food & Beverage	10.2%
Construction	6.1%
Chemicals	4.0%
Real Estate	3.2%
Technology	2.9%
Other	6.5%
Liquidity	4.7%

## Top 10 Individual Holdings

Chocoladefabriken Lindt & Spruengli	6.6%
SGS Ltd	5.7%
Sandoz Group AG	5.4%
Schindler Holding AG	4.9%
Straumann Holding AG	4.7%
Julius Baer Gruppe AG	4.3%
VAT Group AG	3.5%
BELIMO Holding AG	3.0%
Bâloise Holding	2.9%
Galderma Group AG	2.6%

**For marketing and informational purposes:** prospectus, key investor information and the annual and semi-annual reports of the "Von Graffenried Fonds" can be requested for free at Privatbank Von Graffenried AG, Spitalgasse 3, Postfach, 3001 Bern and at 1741 Fund Solutions AG, Burggraben 16, 9000 St. Gallen, or at [www.1741group.com](http://www.1741group.com).

Investments in a product should only be undertaken after having carefully studied the current prospectus. Units of the "Von Graffenried Fonds" may not be offered, sold or delivered within the United States. The information provided herein is neither an offer nor a solicitation to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not include any commissions and costs incurred when subscribing and redeeming units. Commissions and costs have negative impact on the performance. This information neither takes account of the specific or future investment objectives, or of the tax or financial situation or the particular needs of any specific recipient. The information in this document is provided without any warranty or guarantee. It is for information purposes only and is intended solely for the recipient's personal use.